Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae

Diagn Microbiol Infect Dis. 2011 Aug;70(4):561-4. doi: 10.1016/j.diagmicrobio.2011.05.003.

Abstract

Polymyxin B (PB) plus meropenem (MER) or rifampin (RIF) was tested by Etest® method and time-kill assay (TKA) against 14 genetically unique clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. PB + MER: Etest, 43% synergy; TKA, 64% synergy. Concordance between methods was 79%. For PB + RIF: Etest, 21% synergy; TKA, 100% synergy. Concordance between methods was 21%.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Proteins / metabolism*
  • Drug Synergism*
  • Humans
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / enzymology
  • Klebsiella pneumoniae / isolation & purification
  • Meropenem
  • Microbial Sensitivity Tests
  • Microbial Viability / drug effects
  • Polymyxin B / pharmacology*
  • Rifampin / pharmacology*
  • Thienamycins / pharmacology*
  • Time Factors
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Thienamycins
  • beta-Lactamases
  • carbapenemase
  • Meropenem
  • Polymyxin B
  • Rifampin